CHEK2-mutation in Dutch breast cancer families: expanding genetic testing for breast cancer

Muriel A Adank, Frederik J Hes, Wendy A G van Zelst-Stams, M Petrousjka van den Tol, Caroline Seynaeve, Jan C Oosterwijk

Research output: Contribution to journalScientific review

8 Citations (Scopus)


In the majority of breast cancer families, DNA testing does not show BRCA1 or BRCA2 mutations and the genetic cause of breast cancer remains unexplained. Routine testing for the CHEK2*1100delC mutation has recently been introduced in breast cancer families in the Netherlands. The 1100delC mutation in the CHEK2-gene may explain the occurrence of breast cancer in about 5% of non-BRCA1/2 families in the Netherlands. In the general population the CHEK2*1100delC mutation confers a slightly increased breast cancer risk, but in a familial breast cancer setting this risk is between 35-55% for first degree female carriers. Female breast cancer patients with the CHEK2*1100delC mutation are at increased risk of contralateral breast cancer and may have a less favourable prognosis. Female heterozygous CHEK2*1100delC mutation carriers are offered annual mammography and specialist breast surveillance between the ages of 35-60 years. Prospective research in CHEK2-positive families is essential in order to develop more specific treatment and screening strategies.

Original languageDutch
Pages (from-to)A8910
JournalNederlands Tijdschrift voor Geneeskunde
Publication statusPublished - 2015


  • breast cancer
  • families
  • cancer
  • DNA
  • testing
  • BRCA1
  • BRCA2
  • mutation

Fingerprint Dive into the research topics of 'CHEK2-mutation in Dutch breast cancer families: expanding genetic testing for breast cancer'. Together they form a unique fingerprint.

Cite this